Latest Breaking News On - Chief executive officer vas narasimhan - Page 1 : comparemela.com

Novartis Raises Forecast as Sales of New Blockbusters Climb

Novartis Raises Forecast as Sales of New Blockbusters Climb
bnnbloomberg.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bnnbloomberg.ca Daily Mail and Mail on Sunday newspapers.

Giovanni caforioJoerg reinhardtBristol myers squibb coRoche holdingChief executive officer vas narasimhanBristol myers squibbSwiss pharma giants plot different pathsNext blockbusters

Novartis Surges After Forecast Boost Beats Expectations

Novartis Surges After Forecast Boost Beats Expectations
swissinfo.ch - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from swissinfo.ch Daily Mail and Mail on Sunday newspapers.

Harry kirschGiovanni caforioJoerg reinhardtPeter welfordBristol myers squibb coChief financial officer harry kirschChief executive officer vas narasimhanBristol myers squibbSwiss pharma giants plot different pathsNext blockbusters

Big Pharma Targets Smaller Companies With Megadeals Out of Favor

Big Pharma Targets Smaller Companies With Megadeals Out of Favor
bnnbloomberg.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bnnbloomberg.ca Daily Mail and Mail on Sunday newspapers.

Emma walmsleyWouter joustraAlcon incPfizer incJpmorgan health conferenceEli lilly coSandoz groupHaleon plcAmbrx biopharma incAiolos bio incAmgen incInhibrx incAmbrx biopharmaAiolos bioBiotech deal surge dials up buzzHorizon therapeutics

Big Pharma Targets Smaller Companies With Megadeals Out of Favor

Some drugmakers are doubling down on prescription medicines, shedding businesses they view as peripheral.

Wouter joustraEmma walmsleyEli lilly coAlcon incInhibrx incSandoz groupHaleon plcPfizer incAmbrx biopharma incAiolos bio incAmgen incAmbrx biopharmaAiolos bioHorizon therapeuticsChief executive officer vas narasimhan

Novartis Shares Drop on Weak Prostate Cancer Drug Sales

Novartis AG shares slumped after the drugmaker reported earnings that came short of analysts’ estimates on weak revenue from Pluvicto, a prostate cancer treatment that faced supply constraints.

James coneGuy johnsonKriti guptaIntron healthRoche holdingBloomberg televisionMedicines coChief executive officer vas narasimhanSwiss pharma giants plot different pathsNext blockbustersNovartis agProstate cancer treatment